Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (2018)
113 slides from Fisher & Paykel Healthcare's investor day presentation, 2018
Slide 1: US and Mexico Investor Day 2018
US and Mexico Investor Day 2018 21 meer 2018 Fisher & Paykel HEALTHCARE
Slide 2: Morning Agenda
Morning Agenda 8:30am 8:30am 8:45am 9:30am 10:30am 1:00am 11:30am 12:30pm- 1:30pm Welcome Marcus Driller Manufacturing Overview Andrew Somervell Mexico: Delivering Sustainable Growth Raul Sanchez Malena Ortiz Tour of Spence Manufacturing Facility Raul Sanchez Complete facility tour and board coach T
Slide 3: Our approach to Manufacturing
Our approach te ian | > ; Manufacturing _ | 4 y _ eo Dr Andrew Somervell = VP - Products & Technol Fisher & Paykel HEALTHCARE
Slide 4: F&P Manufacturing Approach
F&P Manufacturing Approach * Grow manufacturing capacity to accommodate future volume growth - Modest growth in NZ - Most growth outside NZ * Co-location of R&D and manufacturing in NZ: a competitive advantage * Ongoing efficiency improvements: - Continuous improvement culture - Lean, Six Sigma, Aut
Slide 5: Overview of F&P Manufacturing Facilities
Overview of F&P Manufacturing Facilities * New Zealand: - Pilot manufacturing - 3 buildings, ~19,000m? manufacturing floor space - 4 buildings online ~2020 * Mexico: - 34% of total output in FY18 - ~9,000m? manufacturing floor space - La Encantada: 15 hectares land - Second Mexican facility complete
Slide 6: Planning for our future growth
Planning for our future growth * Space for four ~20,000 m? facilities at La Encantada site in Tijuana, Mexico ¢« Additional manufacturing space planned for future new buildings in Auckland, NZ ¢ Explore additional manufacturing locations: - Further geographic risk mitigation - Further COGS efficienc
Slide 7: Questions?
Questions? Dr Andrew Somervell \ VP - Products & Technology 3 a Fisher & Paykel HEALTHCARE
Slide 8: Mexico: Delivering Sustainable Growth
Mexico: Delivering Sustainable Growth Raul Sanchez General Director Mexico Operations Malena Ortiz > Finance & Group Services Director Fisher & Paykel HEALTHCARE
Slide 9: Source: Tijuana Medical Cluster/Instituto Nacional de Estadística y Geografía (INEGI)
• • • • • Source: Tijuana Medical Cluster/Instituto Nacional de Estadística y Geografía (INEGI) 9
Slide 10: Medical Device Industry in Tijuana
Medical Device Industry in Tijuana >2.4 million employees in the Maquiladora Industry in Mexico in 5,000+ companies. >38,000 people 44+ Medical Device manufacturing plants in Tijuana. Hospitalization 02 |___ 0! Ophthalmology and Surgery ia GBD B8nypro SURGICAL it Yeats 02 Respiratory smiths MERTEDIC
Slide 11: Our Journey
Our Journey E99 999990 Lease agreement signed and fit-out starts. f AAA Fit-out completed. First full face mask shipped. First breathing circuit shipped. First shipments to Europe. Received Japan accreditation. Started HC405 mask production. Second chamber line installed. Commenced production of Eva
Slide 12: La Encantada Campus, Tijuana, Mexico
La Encantada Campus, Tijuana, Mexico < Fisheré.Paykel HEALTHCARE
Slide 13: Melville Building, La Encantada Campus
Melville Building, La Encantada Campus ie Progress” guiding Size m2 22,888 | ¢ > Ke Fisher & Paykel HEALTHCARE
Slide 14: Our People
Our People NUMBER OF EMPLOYEES IN MEXICO 1000 7 900 800 700 600 or 826 667 507 500 469 400 33g 38 300 243 200 100 ° FYI FYI2. FYI3. ~FYI4. -FYIS) «-FYI6. «FYIT.—s FYB 44% Male 56% Female 1,000+ associates 64% Direct 36% Indirect Fisher & Paykel HEALTHCARE u
Slide 15: *Source: Ruiz-Morales y Asociados Firm
*Source: Ruiz-Morales y Asociados Firm 15
Slide 16: Continuing Education
Continuing Education We believe that Educational Program: education is not an 07 Master's Degree opportunity but an investment in our future. O9 Bachelor’s Degree 84 High School Graduates: O2 master’s Degree citys oO cA sites UNIVERSIDAD O1 Bachelor’s Degree 18 High School AIT ue, GliRabas ONBEEES F
Slide 17: Mexico Objectives
Mexico Objectives LICENSE TO SUPPLY CHAIN PROCESS BUSINESS OPERATIONAL OPERATE INTEGRATION FOCUSED INNOVATION EXCELLENCE Fisher & Paykel HEALTHCARE
Slide 18: Operational Excellence
Operational Excellence Fisher’ Paylel Results Enterprise Alignment SA Continuous Improvement People GUIDING PRINCIPLES SUPPORTING CONCEPTS Cultural Enablers l YS Bw? Creating long-term and sustainable solutions rather than leaving temporary fixes in place. Fisher & Paykel HEALTHCARE
Slide 19: People Initiatives
People Initiatives 56+ Kaizen Events 38+ Lean | Six Sigma Certifications Workplace Optimization After Fisher & Paykel
Slide 20: Employee Health & Safety
20 Employee Health & Safety We know that tomorrow matters as much as today. We are one connected family and what makes us family is our commitment to work well and live better. @) Process | 0 Plant 4 Oy Fisher & Paykel HEALTHCARE
Slide 21: Workstation Ergonomics
Workstation Ergonomics After HEALTHCARE
Slide 22: Quality
Quality Fisher & Paykel HEALTHCARE
Slide 23: a THA
oO =) a THA s 0D Sse Y) MS O 12) Cc D O LL oO
Slide 24: Thanks | Gracias
Thanks | Gracias
Slide 25: Questions?
Questions? Raul Sanchez General Director Mexico Operations Malena Ortiz * Finance & Group Services Director Fisher & Paykel HEALTHCARE
Slide 26: Afternoon Agenda
Afternoon Agenda 1:30pm Sustainable Profitable Growth Lewis Gradon Managing Director & CEO 1:40pm Global Sales Approach Paul Shearer Senior VP - Sales & Marketing 2:00pm North American Overview Justin Callahan President - US Operations 2:25pm US Hospital Overview Steve Lacke VP Sales & Marketing - U
Slide 27: Our Aspiration: Sustainably Double Revenue
OUR ASPIRATION: © ® A) @ Sustainably RESPIRATORY CPAP HOSPITAL HOME SURGICAL HUMIDIFICATION THERAPY/OSA RESPIRATORY RESPIRATORY TECHNOLOGIES D fe) U B LI N G SUPPORT SUPPORT our constant currency revenue every 5-6 years. } Fon) SHORT-TERM MEDIUM-TERM LONGER-TERM “CONSTANT CURRENCY Fisher & Paykel oe
Slide 28: Global Sales Approach
4 Global Sales Approach Paul Shearer Senior VP - Sales & Marketing Fisher & Paykel HEALTHCARE
Slide 29: Strong Global Presence
29 Strong Global Presence REVENUE BY REGION Fisheré.Paykel - "12 MONTHS TO 31 MARCH 2018 HEALTHCARE
Slide 30: Multi-Channel Distribution Model
Multi-Channel Distribution Model DIRECT SALES OPERATION Control of sales process Sales force focus Accelerates sales Fisher & Paykel HEALTHCARE
Slide 31: Sales Force Effectiveness and Efficiency
Sales Force Effectiveness and Efficiency « Plan to expand international sales teams * Growth of sales teams in all geographic regions: - North America - Europe - Asia/Pacific - Rest of World ¢« Focus on continuous improvement * Plan to increase sales revenue per person, assisted by: - More products
Slide 32: Clinical Change Process
Clinical Change Process C PRODUCT DEVELOPMENT FEEDBACK D) f YY TRUSTED ADVISOR LONG COMPLEX SALES CYCLE Fisheré.Paykel 32 HEALTHCARE
Slide 33: Importance of the North American Market to FPH
33 Importance of the North American Market to FPH * Largest medical device market in the world - Complex structure - Dynamic * Our largest market - 47% of revenue FY18 * Successful team - Started with 2 people in 1996 - Revenue CAGR ~20% - Now have 150+ sales reps - Driving clinical change Hospitals
Slide 34: Questions?
Questions? Paul Shearer Senior VP - Sales & Marketing Fisher & Paykel HEALTHCARE
Slide 35: North America Overview
North America Overvi Justin Callahan, President Fisher & Paykel Healthcare Inc.
Slide 36: Overview of our North American Business
Overview of our North American Business NORTH AMERICAN REVENUE NORTH AMERICAN EMPLOYEES US$M 350 350 8,000+ direct 300 300 customers 250 250 200 200 150 150 250,000 square 100 100 feet of distribution facilities 50 50 ie) ie) e S ae @ FP PS PS F925 300+ employees Fisheré.Paykel 36 HEALTHCARE
Slide 37: Customers & Distribution Channels
37 Customers & Distribution Channels Therapy Hospital High Flow Therapy NIV Humidification & Masks Invasive Humidification Infant CPAP Infant Resuscitation > > Homecare High Flow Therapy Sleep Therapy NIV Humidification & Masks Invasive Humidification > Distribution Channel Distribution Partners F&P
Slide 38: How does payment work?
38 How does payment work? HOSPITAL Physician Distributors DRG - Diagnosis Related Groups Reimbursement tied to specific diagnosis during inpatient stay. HOMECARE Physician Reimbursement FFS - Fee for Service Reimbursement generally tied to specific product HCPC code for use in the home. Fisher & Pay
Slide 39: Our People and Our Culture
39 Our People and Our Culture North American engagement score Global top quartile for AON Hewitt surveyed companies We believe our people are our strength, and that an engaged workforce drives our success. We know it takes several years for a sales rep to become fully effective due to our long compl
Slide 40: Questions
Quest Justin Callahan, President Fisher & Paykel Healthcare Inc. Fisheré.Paykel HEALTHCARE
Slide 41: US Hospital Overview
US Hospital Overview Steve Lacke, VP Sales & Marketing Steve Wilson, National Sales Manager Fisher & Paykel HEALTHCARE
Slide 42: Our Route to Market
Our Route to Market Fisher &.Paykel HEALTHCARE Group Purchasing Organizations Represent ~98% of US hospitals Combine the buying power of their members Negotiate standardized pricing and contract terms Fisher & Paykel HEALTHCARE
Slide 43: GPO Process
GPO Process + BEG MEMBERSHIP HOSPITAL GPO y, 43 NEGOTIATE: > PRICING Fisher& Paykel > CONTRACTS HEALTHCARE > FEES S Fisher& Paykel HEALTHCARE
Slide 44: Estimated GPO Market Share
44 Estimated GPO Market Share BVizient m Premier mw HealthTrust Intalere m@ Others MARKET SHARE Fisher & Paykel HEALTHCARE
Slide 45: Integrated Delivery Networks (IDNs)
45 Integrated Delivery Networks (IDNs) An IDN is a network of facilities that work together to offer a continuum of care to A a specific geographic area or be utp fe ot market Fa EE a FR # aa “ -RP Negotiate dollar and volume . tah commitments with GPO i . contracted suppliers A BES BE: Oss eeer ~ F
Slide 46: Health of US Hospitals/Regulatory Environment
46 Health of US Hospitals/Regulatory Environment Challenges Healthcare costs and spending exceed rates of inflation - Medicare Office of Actuary estimates healthcare spending will grow at an average rate of 5.8% from 2015 to 2025, 1.3% greater than the expected increase in GDP. Pricing pressure - CM
Slide 47: Our Key Products in the Hospital
47 Our Key Products in the Hospital Resuscitation Invasive Non-invasive ventilation ventilation Nasal high flow Fisheré.Paykel HEALTHCARE
Slide 48: Optiflow Nasal High Flow Therapy
Optiflow Nasal High Flow Therapy Optiflow Nasal High Flow therapy has been clinically proven to reduce the escalation of care when compared to other more conventional therapies (Oxygen Cannula, Oxygen Mask, NIV) Reducing the escalation of care within the acute care facility provides a positive impac
Slide 49: Optiflow - Key Focus of our Sales Team
49 Optiflow - Key Focus of our Sales Team * Sales teams focused on changing clinical practice within the acute care facility to drive adoption: - Physician Education (Pulmonary, Nursing, Respiratory Therapy, Hospitalist, Emergency Medicine) - Increasing the exposure to powerful clinical research - C
Slide 50: Decision makers in the hospital - who's involved?
50 Decision makers in the hospital - who’s involved? Respiratory Therapist (RT) Quality Analysis Diagnose patients, recommend treatments Recommend therapy change Managing all respiratory equipment Educating patients and families Introduce new products/therapies Can be a gateway to the physician Proc
Slide 51: Continuum of Care
Continuum of Care *« Market leading position in invasive ventilation * Working closely with clinicians across the healthcare continuum as Trusted Advisors « Allows opportunities to provide solutions and support across the treatment continuum * Strong partnerships with GPOs that capture our entire po
Slide 52: Questions?
Questions? Steve Lacke, VP Sales & Marketing Steve Wilson, National Sales Manager Fisher & Paykel HEALTHCARE
Slide 53: Afternoon Break
Afternoon Break Fisher & Paykel
Slide 54: Nasal High Flow Therapy: UCSD Perspective
Nasal High Flow Therapy: UCSD Perspective Timothy A. Morris, M.D. Professor of Medicine Division of Pulmonary and Critical Care Medicine Medical Director, Respiratory Care University of California, San Diego Disclosure: Timothy Morris, M.D. will be reimbursed by Fisher & Paykel Healthcare 54 for any
Slide 55: UC San Diego Healthcare
UC San Diego Healthcare • UCSD Hillcrest Medical Center (390 beds) • Jacobs Medical Center (364 beds) • Sulpizio Cardiovascular Center (54 beds) • Average Daily Census: 504 • Annual Discharges: 29,200 • Average Length of Stay: 6.13 • Emergency Visits: 77,603 55
Slide 56: My roles
My roles • Medical Director, Respiratory Care Department • Medical Director, Pulmonary Physiology Lab • Clinical Service Chief, Pulmonary and Critical Care • Critical care physician • Past-president, National Association for Medical Direction of Respiratory Care • President, Respiratory Compromise I
Slide 57: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli 57
Slide 58: Provision of oxygen
Provision of oxygen • FO2 of – 2 LPM NC – 6 LPM NC – 10 LPM face mask – 100% non-rebreather mask 58
Slide 59: Inspiratory flow rates
Inspiratory flow rates 30 L/min 350 L/min 59
Slide 60: Supplied vs entrained air
Supplied vs entrained air 2 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 60
Slide 61: Supplied vs entrained air
Supplied vs entrained air 6 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 61
Slide 62: Supplied vs entrained air
Supplied vs entrained air 60 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 62
Slide 63: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli – Pneumonia – Lung inflammation – Pneumothroax 63
Slide 64: UNIVERSITY of CALIFORNIA
UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE
Slide 65: UNIVERSITY of CALIFORNIA
UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE
Slide 66: UNIVERSITY of CALIFORNIA
e) UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE 66
Slide 67: UNIVERSITY of CALIFORNIA
fe) UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE
Slide 68: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways 68
Slide 69: Humidity
UNIVERSITY of CALIFORNIA H Uu mM id Ity SAN DIEGO ‘SCHOOL OF MEDICINE >) ae
Slide 70: Jungle humidity
so se J Uu n g le h Uu mM d ity SAN DIEGO SCHOOL OF MEDICINE BS 3 = z o 3 ‘8 a hi : 30 a a a & B = a = 3 E40 S = Jan Mar Apr May Jun Jul Aug Annua =9am =3pm
Slide 71: Alveoli are 100% humid at 37 C
Alveoli are 100% humid at 37 C 71
Slide 72: Where does the water come from?
Where does the water come from? Alveolar air Ambient air this week 72
Slide 73: Evaporation from airways
UNIVERSITY of CALIFORNIA B e) SAN DIEGO ‘SCHOOL OF MEDICINE Evaporation from airways Hair-like projections called cilia line the primary bronchus to remove microbes and debris from the interior of the lungs Primary bronchus Goblet cell F#ADAM.
Slide 74: Mucociliary clearance
e) UNIVERSITY of CALIFORNIA M Uu COCi | lary clearan ce SAN DIEGO ‘SCHOOL OF MEDICINE Macrophage To celis, blood Aqueous Layer (Sol) emnien: iiin ae and lymph Ciliated Epithelial 1: Dissolution 2: Mucociliary Clearance Basement Membrane 3: Macrophage phagocytosis 4: Translocation 74
Slide 75: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways – bronchiectasis – cystic fibrosis – chronic bronchitis – asthma – diffuse panbronchiolitis – plastic bronchitis – primary ciliary dyskinesia 75
Slide 76: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation 76
Slide 77: Increase the inspiratory support
Increase the inspiratory support Paw PEEP 77
Slide 78: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation – Neuromuscular weakness – Rib fractures etc. 78
Slide 79: Increase the PEEP
a __ Increase the PEEP SAN DIEGO SCHOOL OF MEDICINE Paw PEEP 79
Slide 80: Normal Alveoli
Normal Alveoli 80
Slide 81: Emphysema
Emphysema 81
Slide 82: Beginning of Exhalation
Beginning of Exhalation Normal Airway Obstruction 82
Slide 83: End of Exhalation
End of Exhalation Normal Airway Obstruction 83
Slide 84: Applied Pressure to Counter PEEPi
Applied Pressure to Counter PEEPi Airway Obstruction Applied Pressure 84
Slide 85: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation – Neuromuscular weakness – Rib fractures etc. – COPD 85
Slide 86: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation • Increase intrathoracic pressure 86
Slide 87: CHF
UNIVERSITY of CALIFORNIA C H F SAN DIEGO ‘SCHOOL OF MEDICINE 87
Slide 88: CHF and positive intra-thoracic pressure
CHF and positive intra-thoracic pressure 88
Slide 89: Positive intra-thoracic pressure during CHF
Positive intra-thoracic pressure during CHF… • decreases venous return • reduces right ventricle bulging into left ventricle • decreases left ventricle work 89
Slide 90: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation • Increase intrathoracic pressure – Cardiomyopathy – Congestive heart failure 90
Slide 91: Clinical niches at UCSD
Clinical niches at UCSD • Provide oxygen to alveoli Routine use • Provide water to airways Growing use • Mechanical support to ventilation Beginning use • Increase intrathoracic pressure Beginning use 91
Slide 92: Thank you
a O UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE Thank you 92
Slide 93: US Homecare Overview
US Homecare Overview Justin Callahan, President of US Operations Steve Polgar, VP Sales & Marketing ») Fisher & Paykel HEALTHCARE
Slide 94: OSA Market Update
94 OSA Market Update * Growing market - new patients being diagnosed * DME consolidation in some regions though still a very fragmented market with ~3,000 DMEs nationally * Reimbursement stabilized *« Proposed changes to competitive bidding look positive for the industry « Providers continuing to em
Slide 95: Our Leading-Edge Masks
95 Our Leading-Edge Masks oy Simplus” Eson"2 Brevida’ * Significant focus building awareness and confidence with sleep physicians Fisheré.Paykel HEALTHCARE
Slide 96: Mask Matters Most Campaign
Mask Matters Most Campaign The Mask Matters Most’ F&P SIMPLUS™ =a
Slide 97: Rest. Assured.
97 Rest. Assured. “My dad was always making things, fixing something for a neighbour, or building small yachts. He always encouraged me to think about how to improve and make iterations to designs, continuously improving and learning from previous mistakes. But more importantly to never give up and
Slide 98: Our focus in OSA
98 Our focus in OSA * Continue to grow with new patient starts - Patient satisfaction - Efficiencies for the homecare provider (acceptance and trailing revenues) - Satisfies the referral source - Outstanding performance and choice drives the interface to be viewed separately to the CPAP device Fishe
Slide 99: F&P SleepStyle - Freedom in Simplicity
F&P SleepStyle - Freedom in Simplicity *« US 510(K) regulatory clearance recently received * Due for US release early 2019 « Premium positioning, comprehensive comfort features, patient centered Fully released in Canada - In Canada, SleepStyle has been well received by clinicians and patients Fisher
Slide 100: MyAirvo - Nasal High Flow in the Home
0 MyAirvo - Nasal High Flow in the Home « Primary patient group is chronic ¢ First significant clinical publication: * COPD is a progressive incurable disease * Data suggests with humidified high flow obstructive pulmonary disease (COPD) - International Journal of COPD that consumes significant heal
Slide 101: MyAirvo - Building awareness
v1 MyAirvo - Building awareness f é + Building awareness among the medical community * Connecting pulmonologist with homecare providers to develop pathways for patient access in the home - Early adopters - Monthly rental direct to patients - Cash pay patients — Direct coverage through vertical healt
Slide 102: Questions?
Questions? Justin Callahan, President of US Operations Steve Polgar, VP Sales & Marketing a») Fisher & Paykel HEALTHCARE 2
Slide 103: HCD COPD Program
HCD COPD Program The COPD Program offers comprehensive, personalized care for people with Chronic Obstructive Pulmonary Disease (COPD) John Olivas, President Rodolfo Blain, VP HME 103
Slide 104: Disclosure
Disclosure John Olivas and Rodolfo Blain will be reimbursed by Fisher & Paykel Healthcare for any expenses incurred in connection with their participation in today’s event. 104
Slide 105: Equipment for Improved Living
Equipment for Improved Living Durable Medical Equipment Negative Pressure Wound Therapy Feeding Pumps Hospital Beds Tens Units Gel Mattresses Incontinence Supplies Low Air Loss Mattresses Ventilators Trapeze Bars Oxygen Concentrators Wheelchairs O2 Conserving Devices Bariat
Slide 106: COPD Program Goals
COPD Program Goals Prevent disease progression Relieve symptoms Improve exercise tolerance Improve health status Prevent and treat complications Prevent and treat exacerbations, reducing hospital admissions Improve overall quality of life People who learn about their COPD and treatme
Slide 107: COPD Education
COPD Education What is COPD Respiratory System What Happens to Your lungs with COPD Medication Delivery Devices Metered Dose Inhaler and Proper Use Nebulizer and Proper Use Albuterol Home Oxygen When to call your Primary Care Physician 107
Slide 108: Standard COPD Program Length
Standard COPD Program Length The standard COPD program stay will last 5 weeks with an extra 1 week to be reserved for as needed (PRN). The first week will run Monday through Friday with scheduled 1 hour daily sessions as follows: Week 1, Monday through Friday with scheduled 1 hour daily sessions t
Slide 109: COPD Program and Airvo
COPD Program and Airvo INDICATION FOR AIRVO 2 HIGH FLOW HUMIDIFICATION Reoccurring Hospitalizations due to COPD exacerbation (Yellow Zone) Potential for/or Presence of Atelectasis Bronchospasm Bronchiectasis Need for Hydration and of Retained Secretions Need for Heated Humidification – I
Slide 110: Airvo Case 1
Airvo Case 1 70 y/o Hispanic female presented with diagnosis of COPD 3 prior hospitalizations last one 04/03/18 Admitted into COPD program on 05/16/18 w/Airvo Followed for the initial four week COPD program visits in which her vital signs remained within normal limits, but with a noted impro
Slide 111: Airvo Case 2
Airvo Case 2 83 y/o Hispanic male presented with diagnosis of COPD Multiple hospitalizations for exacerbation of his COPD Most resent hospitalization was in 06/17/18 for 10 days Admitted post hospitalization 06/28/18 His bilateral breath sounds were with rhonchi to upper lobes and diminish
Slide 112: Airvo Case 3
Airvo Case 3 66 y/o Hispanic male presented with diagnosis of COPD Two prior hospitalizations for COPD exacerbation admitted into COPD program on 07/18/18 patient completed the COPD program with unremarkable results and no visits to the ER and no hospitalizations. 112
Slide 113: Lewis Gradon
Lewis Gradon Fisher & Paykel HEALTHCARE